Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > LATEST
LATEST
-
REGULATORY PMDA Reviewing Safety Risks for Joyclu, Lixiana, Keytruda
January 7, 2025
-
ORGANIZATION As 2025 Begins, Industry Leaders Renew Resolve towards Next Reforms
January 6, 2025
-
REGULATORY MHLW’s FY2025 Budget Includes 7.7 Billion Yen to Drive Drug Commercialization
January 6, 2025
-
REGULATORY Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
-
REGULATORY Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
-
ORGANIZATION DPP Head, Industry Leaders United towards Stopping Off-Year Price Revisions
November 29, 2024
-
REGULATORY MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
-
BUSINESS Japan Pharma Market Projected to Cross 12 Trillion Yen in FY2029: IQVIA
November 29, 2024
-
REGULATORY Japan to Require Drug Makers to Set Up Legal Post of “Stable Supply Manager”
November 29, 2024
-
REGULATORY Japan Set to Put Up 100 Billion Yen to Support Pharma under Economic Package
November 29, 2024
-
BUSINESS Leqembi Now Available in South Korea: Eisai
November 29, 2024
-
REGULATORY Orphan Tag Given to Renalys’ IgA Nephropathy Therapy and 13 More Drugs
November 29, 2024
-
COLUMN How to Be a Country Manager
November 29, 2024
-
ORGANIZATION PhRMA Wants No Off-Year Price Cuts, Urges Japan Not to Backslide: Chair
November 28, 2024
-
REGULATORY Scrap Off-Year Price Revisions, Smaller Japan Firms Face Uphill Battle: DPP Exec
November 28, 2024
-
REGULATORY DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
-
REGULATORY Panel OKs 1-Year Extension of HPV Catch-Up Vaccinations, with Strings Attached
November 28, 2024
-
BUSINESS Pfizer Files Migraine Drug Rimegepant in Japan
November 28, 2024
-
REGULATORY Sakigake Tag Granted for Iclepertin, Brogidirsen
November 28, 2024
-
COMMENTARY MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…